Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brasofensine NeuroSearch.

P Yu1

  • 1Neuropsychiatric Research Unit, Department of Psychiatry, A114 Medical Research Building, University of Saskatchewan, Saskatoon, Saskatchewan, CA S7N 0WO, Canada. yup@sask.usask.ca

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical evaluation of different ophthalmic optical coherence tomography devices using a retinal biomimetic phantom].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2026
Same author

[The application of superselective ophthalmic artery thrombolysis in the treatment of central retinal artery occlusion].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2025
Same author

Extracellular Z-DNA Enhances Cariogenicity of Biofilm.

Journal of dental research·2025
Same author

[Study on the correlation between urinary calcium levels and severity and prognosis of chronic kidney disease].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi·2025
Same author

Zhou et al. Reply.

Physical review letters·2024
Same author

Erratum: Ubiquitous Non-Majorana Zero-Bias Conductance Peaks in Nanowire Devices [Phys. Rev. Lett. 123, 107703 (2019)].

Physical review letters·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Brasofensine, a dopamine reuptake inhibitor, was investigated for Parkinson's disease treatment. Development faced setbacks, including partner withdrawal and regulatory hurdles, impacting timelines and sales projections for this potential Parkinson's therapy.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Development

Background:

  • Brasofensine (NS-2214) is a novel dopamine reuptake inhibitor developed for Parkinson's disease (PD).
  • The drug progressed to Phase I and II clinical trials, indicating early-stage therapeutic potential.
  • Collaboration with Bristol-Myers Squibb (BMS) was terminated in 1999 due to financial and regulatory challenges.

Purpose of the Study:

  • To evaluate the efficacy and safety of brasofensine as a treatment for Parkinson's disease.
  • To establish a development and marketing strategy following the withdrawal of a key partner.
  • To seek new licensing agreements to accelerate drug development and market entry.

Main Methods:

  • Phase I and II clinical trials were conducted in the US and Denmark.

Related Experiment Videos

  • Planned controlled trials included comparisons with placebo and L-DOPA over at least three months.
  • Preclinical studies, including long-term animal safety tests (monkeys), were required by regulatory bodies.

    • Main Results:

    • Initial clinical trials (Phase I/II) were completed.
    • Regulatory discussions with the FDA outlined requirements for further preclinical studies before advancing clinical development.
    • Financial analysts provided sales predictions, estimating significant market potential if the drug reached commercialization.

    Conclusions:

    • Further preclinical research and regulatory discussions were necessary for brasofensine's continued development.
    • The drug's path to market was contingent on successful completion of further studies and securing new partnerships.
    • Despite development challenges, brasofensine held projected significant market potential for Parkinson's disease treatment.